Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cyclopharm
Kingsgrove, New South Wales, Australia
- Ownership
- Private
- Employees
- ~87
- Development stage
- Other
01
Overview
Cyclopharm's Technegas is in commercial use in 65 countries and received US FDA approval in late 2023. Clinical evidence supports superior diagnostic accuracy for pulmonary embolism versus alternatives, and clinical development is ongoing for new indications such as COPD, asthma, and lung cancer[1][2][3][5].
- Therapeutic areas
- OncologyInfectious DiseasesPulmonologyCardiovascular
- Modalities
- RadiopharmaceuticalDevice
- Industry
- Medical Imaging
02
Partnerships
US Veterans Health Administration (distribution agreement for Technegas across 120+ hospitals)Largest US private hospital network (distribution agreement for Technegas at 168+ hospitals)
Beyond the preview
Go deeper on Cyclopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyclopharm.